Pharmacotyping of hypokalaemic salt-losing tubular disorders
| Autor: | Stephan C. Reinalter, Melanie Peters, Nikola Jeck, Hannsjörg W. Seyberth |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
medicine.medical_specialty
Renal Tubular Transport Inborn Errors Genotype Physiology business.industry Metabolic alkalosis Furosemide Bartter Syndrome Hypokalemia Gitelman syndrome medicine.disease Bartter syndrome Hyperaldosteronism Amiloride Endocrinology Phenotype Internal medicine Terminology as Topic medicine ROMK Chloride channel Humans business Diuretics medicine.drug |
| Zdroj: | Acta physiologica Scandinavica. 181(4) |
| ISSN: | 0001-6772 |
| Popis: | UNLABELLED Long standing confusion exists in the terminology of hypokalaemic salt-losing tubulopathies (SLTs). SLTs are autosomal recessively transmitted and characterized by normotensive secondary hyperreninism/hyperaldosteronism with hypokalaemic metabolic alkalosis. Historically, four phenotypical variants have been described: (1) the (classic) Bartter syndrome (cBS), (2) the hypomagnesaemic hypocalciuric Gitelman syndrome (GS), (3) the hypercalciuric hyperprostaglandin-E-syndrome (HPS) or antenatal Bartter syndrome (aBS) and (4) the hyperprostaglandin-E-syndrome with sensorineural deafness (HPS + SND). The latter two syndromes are the most severe variants with antenatal manifestation with polyhydramnios and life-threatening course of salt- and water-loss. Defects in five renal membrane proteins involved in electrolyte reabsorption have been identified: In HPS-patients mutations in (1) either the furosemide-sensitive sodium-potassium-chloride cotransporter NKCC2, or (2) in the potassium channel ROMK have been identified, and (3) HPS + SND is caused by mutations in the beta-subunit of the chloride channels ClC-Kb and -Ka (named barttin), all mimicking the major pharmacological effects of furosemide with minor potassium-wasting in ROMK-patients as seen in patients treated with simultaneous furosemide and amiloride, and minor calcium-wasting in Barttin-patients resembling the combination of furosemide and thiazides. (4) cBS is caused by mutations in the chloride channel ClC-Kb with similar clinical characteristics as seen under combination of thiazides and furosemide, (5) GS is caused by mutations in the thiazide-sensitive sodium-chloride cotransporter NCCT resembling the effect of long-term thiazide administration. CONCLUSION The combination of pharmacology and genetics suggests a new terminology for the above described SLTs: Furosemide-like-SLT for HPS caused by NKCC2-mutations, furosemide/amiloride-like-SLT for HPS caused by ROMK-mutations, furosemide/thiazide-like-SLT for HPS + SND, thiazide/furosemide-like-SLT for cBS, and thiazide-like-SLT for GS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|